Benson Ogunjimi1, Frank Buntinx2, Stephaan Bartholomeeusen3, Ita Terpstra4, Inke De Haes5, Lander Willem6, Steven Elli7, Joke Bilcke8, Pierre Van Damme9, Samuel Coenen10, Philippe Beutels11. 1. Centre for Health Economics Research & Modeling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium; Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Hasselt University, Agoralaan Building D, 3590 Diepenbeek, Belgium. Electronic address: Benson.ogunjimi@uantwerp.be. 2. Department of General Practice and Intego Registry, Catholic University of Leuven, Kapucijnenvoer 33, Blok J, Bus 7001, 3000 Leuven, Belgium; Research Institute Caphri, University of Maastricht, Universiteitssingel 40, 6229 Maastricht, The Netherlands. Electronic address: frank.buntinx@med.kuleuven.be. 3. Department of General Practice and Intego Registry, Catholic University of Leuven, Kapucijnenvoer 33, Blok J, Bus 7001, 3000 Leuven, Belgium. Electronic address: stefaan.bartholomeeusen@uantwerp.be. 4. Centre for Health Economics Research & Modeling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. Electronic address: ita.terpstra@student.uantwerp.be. 5. Centre for Health Economics Research & Modeling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. Electronic address: inke.dehaes@student.uantwerp.be. 6. Centre for Health Economics Research & Modeling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. Electronic address: lander.willem@uantwerp.be. 7. Department of General Practice and Intego Registry, Catholic University of Leuven, Kapucijnenvoer 33, Blok J, Bus 7001, 3000 Leuven, Belgium. Electronic address: steven.elli@med.kuleuven.be. 8. Centre for Health Economics Research & Modeling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. Electronic address: joke.bilcke@uantwerp.be. 9. Centre for the Evaluation of Vaccination (CEV), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. Electronic address: pierre.vandamme@uantwerp.be. 10. Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium; Centre for General Practice, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. Electronic address: samuel.coenen@uantwerp.be. 11. Centre for Health Economics Research & Modeling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium; School of Public Health and Community Medicine, The University of New South Wales, Level 3, Samuels Building Gate 11, Botany Street, 2052 Sydney, Australia. Electronic address: philippe.beutels@uantwerp.be.
Abstract
OBJECTIVES: We assessed the association between herpes zoster (HZ) and herpes simplex (HS) occurrence whilst controlling for risk factors of HZ. METHODS: Using a Belgian general practitioner network, a retrospective cohort study with 3736 HZ patients and 14,076 age-gender-practice matched controls was performed, covering over 1.5 million patient-years. Multiple logistic regression was used with HZ as outcome and several diagnoses (malignancy, depression, diabetes mellitus, auto-immune diseases, asthma, multiple sclerosis, HIV, fractures), medications (systemic corticosteroids, biologicals, vaccination), HS and other infections as variables. RESULTS: HS was significantly associated with HZ for all analysed time intervals (up to five years) post HZ (OR of 3.51 [2.09 5.88] 95%CI one year post HZ) and to a lesser extent for time ranges pre HZ. Registration of other infections was significantly associated with HZ in all time intervals pre and post HZ (OR up to 1.37). Malignancy up to five years pre HZ, depression up to one year pre or post HZ, fractures up to two years pre HZ, asthma, auto-immune diseases, and immunosuppressive medication one year pre or post HZ were also associated with HZ. CONCLUSIONS: HZ and HS occurrences are significantly associated and potentially share a common susceptibility beyond the known risk factors.
OBJECTIVES: We assessed the association between herpes zoster (HZ) and herpes simplex (HS) occurrence whilst controlling for risk factors of HZ. METHODS: Using a Belgian general practitioner network, a retrospective cohort study with 3736 HZ patients and 14,076 age-gender-practice matched controls was performed, covering over 1.5 million patient-years. Multiple logistic regression was used with HZ as outcome and several diagnoses (malignancy, depression, diabetes mellitus, auto-immune diseases, asthma, multiple sclerosis, HIV, fractures), medications (systemic corticosteroids, biologicals, vaccination), HS and other infections as variables. RESULTS: HS was significantly associated with HZ for all analysed time intervals (up to five years) post HZ (OR of 3.51 [2.09 5.88] 95%CI one year post HZ) and to a lesser extent for time ranges pre HZ. Registration of other infections was significantly associated with HZ in all time intervals pre and post HZ (OR up to 1.37). Malignancy up to five years pre HZ, depression up to one year pre or post HZ, fractures up to two years pre HZ, asthma, auto-immune diseases, and immunosuppressive medication one year pre or post HZ were also associated with HZ. CONCLUSIONS: HZ and HS occurrences are significantly associated and potentially share a common susceptibility beyond the known risk factors.
Authors: Sigrun A J Schmidt; Sinéad M Langan; Henrik S Pedersen; Henrik C Schønheyder; Sara L Thomas; Liam Smeeth; Kathryn E Mansfield; Henrik T Sørensen; Harriet J Forbes; Mogens Vestergaard Journal: Am J Epidemiol Date: 2018-05-01 Impact factor: 4.897
Authors: Pieter Meysman; Nicolas De Neuter; Esther Bartholomeus; George Elias; Johan Van den Bergh; Marie-Paule Emonds; Geert W Haasnoot; Steven Heynderickx; Johan Wens; Nele R Michels; Julien Lambert; Eva Lion; Frans H J Claas; Herman Goossens; Evelien Smits; Pierre Van Damme; Viggo Van Tendeloo; Philippe Beutels; Arvid Suls; Geert Mortier; Kris Laukens; Benson Ogunjimi Journal: Immunogenetics Date: 2017-12-01 Impact factor: 3.330